CliffBio
small molecule

NEOSTIGMINE METHYLSULFATE

NEOSTIGMINE METHYLSULFATE

Loss of exclusivity—loss of exclusivity
CompanyAmphastar Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEOSTIGMINE METHYLSULFATE
Active ingredientNEOSTIGMINE METHYLSULFATE
Strength5MG/10ML (0.5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2017
Marketing statusRX

More from Amphastar Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NEOSTIGMINE METHYLSULFATE patent cliff — loss of exclusivity — | CliffBio